Literature DB >> 33424613

Use of Cardiovascular Drugs for Primary and Secondary Prevention of Cardiovascular Disease Among Rural-Dwelling Older Chinese Adults.

Lin Cong1,2,3, Yifei Ren1, Tingting Hou1,2,3, Xiaolei Han1, Yi Dong1, Yongxiang Wang1,2,3, Qinghua Zhang1,2,3, Rui Liu1, Shan Xu1, Lidan Wang1, Yifeng Du1,2,3, Chengxuan Qiu2,4.   

Abstract

Cardiovascular risk factors and related disorders are common among older adults, and use of various classes of cardiovascular (CV) drugs could reduce the risk of cardiovascular disease (CVD). However, data are sparse with regard to the use of CV drugs among rural-dwelling older adults in China. Therefore, this population-based study aimed to describe use of CV drugs among older adults living in the rural communities in China, while taking into account the use of CV drugs for primary and secondary prevention of CVDs. This study included 5,246 participants (age ≥65 years; 57.17% women; 40.68% illiteracy) in the baseline examination of the MIND-China study. In March-September 2018, data on health-related factors, CVDs (ischemic heart disease, atrial fibrillation, heart failure, and stroke), and CV drug use were collected via face-to-face survey, clinical examination, and laboratory tests. We classified CV drugs according to the Anatomical Therapeutic Chemical classification system for western medications and specific cardiovascular effects for the products of traditional Chinese medicine (TCM). We conducted descriptive analysis. The overall prevalence of major cardiovascular risk factors ranged from 14.30% in diabetes and 23.81% in dyslipidemia to 66.70% in hypertension, and CVDs affected 35.07% of all participants (36.28% in women vs. 33.47% in men, p = 0.035). In the total sample, calcium channel blockers (C08) were most commonly used (10.39%), followed by TCM products (7.64%), hypoglycemic agents (A10, 4.73%), renin-angiotensin system (RAS)-acting agents (C09, 4.61%), and lipid-lowering agents (C10, 4.17%). The proportions of CV drugs for primary prevention (i.e., use of CV drugs among people without CVD) were 3.14% for antithrombotic agents (mainly aspirin), 1.38% for lipid-lowering agents, and 3.11% for RAS-acting agents; the corresponding figures for secondary prevention (i.e., use of CV drugs among people with CVD) were 13.97%, 9.35%, and 7.39%. In conclusion, despite highly prevalent cardiovascular risk factors and CVDs, a fairly low proportion of the rural-dwelling older adults take CV medications for primary and secondary prevention. Notably, TCM products are among the most commonly used CV drugs. These results call for additional efforts to promote implementation of the evidence-based recommendations for prevention of CVDs in the primary care settings.
Copyright © 2020 Cong, Ren, Hou, Han, Dong, Wang, Zhang, Liu, Xu, Wang, Du and Qiu.

Entities:  

Keywords:  cardiovascular disease; cardiovascular drugs; prevalence; prevention; rural

Year:  2020        PMID: 33424613      PMCID: PMC7793651          DOI: 10.3389/fphar.2020.608136

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  9 in total

1.  Associations of the Glycaemic Control of Diabetes with Dementia and Physical Function in Rural-Dwelling Older Chinese Adults: A Population-Based Study.

Authors:  Yanhong Jia; Rui Liu; Shi Tang; Dongming Zhang; Yongxiang Wang; Lin Cong; Tingting Hou; Juan Ren; Yifeng Du
Journal:  Clin Interv Aging       Date:  2021-08-13       Impact factor: 4.458

2.  Association of Cardiovascular Health Metrics with Dementia in Rural Chinese Older Adults: A Population-Based Study.

Authors:  Xiaolei Han; Yongxiang Wang; Ziying Jiang; Yuanjing Li; Yi Dong; Lin Cong; Tingting Hou; Yajun Liang; Erika J Laukka; Yifeng Du; Chengxuan Qiu
Journal:  Clin Interv Aging       Date:  2022-06-10       Impact factor: 3.829

3.  Olfactory Impairment Among Rural-Dwelling Chinese Older Adults: Prevalence and Associations With Demographic, Lifestyle, and Clinical Factors.

Authors:  Yi Dong; Yongxiang Wang; Keke Liu; Rui Liu; Shi Tang; Qinghua Zhang; Ingrid Ekström; Erika J Laukka; Yifeng Du; Chengxuan Qiu
Journal:  Front Aging Neurosci       Date:  2021-04-12       Impact factor: 5.750

4.  Protocol of the Inner Mongolian Healthy Aging Study (IMAGINS): a longitudinal cohort study.

Authors:  Yunfeng Xi; Qiuyue Tian; Buqi Na; Ke Han; Mingrui Duan; Xingguang Zhang; Wenrui Wang; Youxin Wang
Journal:  BMC Public Health       Date:  2022-01-17       Impact factor: 3.295

5.  Self-reported sleep characteristics associated with dementia among rural-dwelling Chinese older adults: a population-based study.

Authors:  Rui Liu; Shi Tang; Yongxiang Wang; Yi Dong; Tingting Hou; Yifei Ren; Lin Cong; Keke Liu; Yu Qin; Shireen Sindi; Yifeng Du; Chengxuan Qiu
Journal:  BMC Neurol       Date:  2022-01-03       Impact factor: 2.474

6.  Genetic Effects of NDUFAF6 rs6982393 and APOE on Alzheimer's Disease in Chinese Rural Elderly: A Cross-Sectional Population-Based Study.

Authors:  Yingzhe Cheng; Yuanjing Li; Xiaoyan Liang; Pin Wang; Wenxin Fa; Cuicui Liu; Yongxiang Wang; Keke Liu; Nan Wang; Yifeng Du
Journal:  Clin Interv Aging       Date:  2022-02-24       Impact factor: 4.458

7.  Health status and risk profiles for brain aging of rural-dwelling older adults: Data from the interdisciplinary baseline assessments in MIND-China.

Authors:  Yongxiang Wang; Xiaolei Han; Xianda Zhang; Zhonglin Zhang; Lin Cong; Shi Tang; Tingting Hou; Cuicui Liu; Xiaojuan Han; Qinghua Zhang; Jianli Feng; Ling Yin; Lin Song; Yi Dong; Rui Liu; Yuanjing Li; Tiia Ngandu; Miia Kivipelto; Heather Snyder; Maria Carrillo; Jonas Persson; Laura Fratiglioni; Lenore J Launer; Jianping Jia; Yifeng Du; Chengxuan Qiu
Journal:  Alzheimers Dement (N Y)       Date:  2022-04-14

8.  Baseline Ratio of Soluble Fas/FasL Predicts Onset of Pulmonary Hypertension in Elder Patients Undergoing Maintenance Hemodialysis: A Prospective Cohort Study.

Authors:  Xiao-Han Ding; Xiaoliang Chai; Jin Zheng; Hong Chang; Wenxue Zheng; Shi-Zhu Bian; Ping Ye
Journal:  Front Physiol       Date:  2022-03-01       Impact factor: 4.566

9.  Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018.

Authors:  Manuel E Machado-Duque; Diego Arturo Garcia; Melissa Hiromi Emura-Vélez; Andrés Gaviria-Mendoza; Jorge E Machado-Alba
Journal:  J Prim Care Community Health       Date:  2021 Jan-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.